Scientists at the University of Cambridge have developed a vaccine using artificial intelligence to create what they describe as a fundamentally new approach to immunization. The key innovation involves an AI system that analyzed genetic codes from multiple coronaviruses to design a single “super-antigen” capable of training the immune system to recognize and fight an entire family of viruses, rather than just individual strains.
The vaccine was engineered to target all coronaviruses, including all Covid variants and animal viruses with pandemic potential. Researchers said this represents the first instance where an antigen designed entirely by AI has undergone human trials. The approach addresses a persistent challenge in vaccine development: viruses that mutate rapidly, causing previously effective vaccines to become outdated. Traditional vaccines are designed based on current viral strains, while this AI-generated antigen theorizes broader, more durable protection.
Early trials involving 39 people assessed safety, with findings published in the Journal of Infection showing the vaccine generated an “modest” immune response. A second study with approximately 200 participants is designed to provide more comprehensive data on immune system activation. While results so far have generated interest in the scientific community, researchers acknowledge the work remains in preliminary stages.
Beyond coronaviruses, the Cambridge team is pursuing additional applications. Animal research is underway on universal seasonal flu vaccines that would not require annual reformulation and an H5N1 bird flu vaccine as a pandemic precaution. The team is also investigating vaccines for viral hemorrhagic fevers, including Ebola species, particularly relevant given an ongoing outbreak in the Democratic Republic Congo caused by a species currently lacking an available vaccine.
Scientific experts have characterized the findings as promising. Researchers not involved in the study noted that artificial intelligence could fundamentally accelerate vaccine development by predicting immune system responses and shortening timelines. Government officials described the work as a demonstration of combining research expertise with AI technology to advance medical treatments.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI